Mechanism of Action - Jakavi
Uncontrolled JAK/STAT signalling is characteristic of both polycythaemia vera (PV) 1–5 a nd for myelofibrosis (MF). 6
JAKs are tyrosine kinases that transmit signals from cytokine or growth factor receptors to the cell...Twitter Linkedin Facebook Pinterest Google plusPatient Resources - Jakavi
Safety Profile - Kisqali
As with every medicine, when using Kisqali, side effects can occur. In the case of serious or unacceptable side effects, it is possible that a dose adjustment is necessary. Here you can read more about the side effects of Kisqali.Twitter Linkedin Facebook Pinterest Google plusDosing - Kisqali
4 week dosing schedule 1 INITIAL DOSING: 600 mg/day (3 tablets of 200 mg) KISQALI in combination with a NSAI Please refer to the Summary of Product Characteristics (SmPC) of the aromatase inhibitor for...Twitter Linkedin Facebook Pinterest Google plusReimbursement - Kisqali
Kisqali ® is reimbursed in Belgium, you can find the reimbursement conditions on the INAMI website .
E-HealthYou can request reimbursement by...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action - Kisqali
Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6, resulting in 50% inhibition (IC50) values of 0.01 (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated upon binding to D-...
Twitter Linkedin Facebook Pinterest Google plusPatient Resources - Scemblix
Practical information - Scemblix
ESH Berlin 2023 Highlights
×